BreStem Therapeutics, Inc.

**BreStem Therapeutics, Inc.** is a clinical stage biotech company dedicated to combatting fatal lung diseases through innovative stem cell and exosome therapies. The company is at the forefront of the lung regeneration revolution with diverse product platforms that encompass cell therapy, bioengineering, and smart nanotechnology. Their goal is to develop and bring to market advanced products utilizing Lung Spheroid Cells as a treatment option for individuals living with pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and other chronic, ultimately fatal lung diseases with no current cure. Led by a world-class leadership team with over 40 years of experience in respiratory research and bioengineering, BreStem is developing a diverse pipeline of patient-specific cell therapy as well as "off-the-shelf" ready stem cell products to provide readily available cell-free therapies more reliably and at greater scale to more patients around the world. The company’s lead candidate **BRS101 (autologous lung spheroid cells)** has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions. The company’s second candidate **BRS201 (lung spheroid secretome/exosome)** is currently at the preIND development stage. BreStem Therapeutics, Inc., founded in **2017** and headquartered in the **United States**, is committed to transforming the lives of patients with respiratory diseases and their families. With a focus on biotechnology and healthcare, BreStem represents an innovative player in the industry, offering potential for substantial impact and growth.